PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT) announced the international launch of the HYDROS Robotic System on March 12, 2026, beginning in the UK, with additional international expansion planned in 2026. HYDROS is described as the first AI-enabled robotic platform for Aquablation therapy to treat benign prostatic hyperplasia (BPH).
The system combines AI-interpreted real-time ultrasound, advanced image-guided treatment planning, and robotic precision to deliver personalized, anatomy-specific Aquablation procedures. The company said HYDROS aims to support scalable adoption across care settings while preserving sexual and urinary function, and to expand surgical choice for men living with BPH.
Positive
- International commercial launch in UK on March 12, 2026
- First AI-enabled robotic platform for Aquablation therapy
- AI-interpreted real-time ultrasound and image-guided planning
Negative
- Initial rollout limited to UK; broader expansion planned later in 2026
News Market Reaction – PRCT
On the day this news was published, PRCT declined 6.04%, reflecting a notable negative market reaction. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $96M from the company's valuation, bringing the market cap to $1.50B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PRCT gained 15.02% on the HYDROS AI-enabled launch, while close medical-device peers showed mixed, mostly modest moves between about -5% and +1–2%, indicating a stock-specific reaction rather than a broad sector shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Investor Day outlook | Positive | -15.1% | Management detailed multi‑year growth, margin and EBITDA targets for Aquablation leadership. |
| Feb 25 | Q4 2025 earnings | Positive | +2.1% | Reported strong 2025 revenue and procedure growth with higher 2026 revenue guidance and margins. |
| Feb 23 | Earnings timing update | Neutral | -0.4% | Adjusted dates for Q4 earnings call and Investor Day due to travel disruptions. |
| Feb 04 | Investor conferences | Neutral | -5.3% | Announced participation in two March 2026 healthcare investor conferences with webcast access. |
| Jan 26 | Event scheduling | Neutral | +4.0% | Scheduled Q4 2025 earnings call and in‑person Investor Day at NASDAQ headquarters. |
Reactions to news have been mixed: earnings and scheduling updates saw modest moves, while an optimistic Investor Day with strong growth targets coincided with a sharp selloff, suggesting occasional negative reactions even to constructive long-term messaging.
Recent PRCT news has focused on growth and investor outreach. The Feb 25, 2026 earnings report highlighted strong 2025 revenue expansion and higher 2026 guidance, with a modestly positive price move. An Investor Day on Feb 26, 2026 outlined multi‑year revenue, margin and EBITDA improvement targets but the stock fell over 15%. Several conference and timing announcements had relatively small reactions. Against this backdrop, today’s AI-enabled HYDROS launch extends the Aquablation growth story with a concrete international expansion milestone.
Market Pulse Summary
The stock moved -6.0% in the session following this news. A negative reaction despite the HYDROS AI-enabled launch would fit PRCT’s history of occasionally selling off on constructive updates, as seen after the Investor Day’s growth targets. Shares sitting below the 200-day MA and far under the 52-week high highlight existing skepticism embedded in the price. Investors would need to weigh the long-term international expansion potential of Aquablation against prior volatility around guidance and strategic communications.
AI-generated analysis. Not financial advice.
UK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026
SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH).
HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution.
Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients.
“Many men living with BPH remain on long-term medication or delay surgery because they are concerned about potential trade-offs between symptom relief and side effects,” said Larry Wood, President & CEO, PROCEPT BioRobotics. “The HYDROS Robotic System expands international access to a clinically validated, next-generation AI-enabled robotic solution that delivers durable symptom relief while preserving quality of life. We are proud to bring this innovation to physicians and patients across the UK and to continue expanding our international footprint.”
“The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment,” said Mr. Neil Barber, Consultant Urological Surgeon. “By combining surgeon judgement with robotic precision, Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH.”
Healthcare providers can learn more about the HYDROS Robotic System at: https://www.procept-biorobotics.com/healthcare-providers/hydros-robotic-system.
About Aquablation Therapy
Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion.
About PROCEPT BioRobotics® Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Media Contact:
Matt Basco
Vice President, Investor Relations and Business Operations
PROCEPT BioRobotics
m.bacso@procept-biorobotics.com
FAQ
What did PROCEPT announce about the HYDROS Robotic System on March 12, 2026 (PRCT)?
How does the HYDROS system differ from previous Aquablation platforms for PRCT investors?
What clinical benefits does PROCEPT claim for Aquablation delivered by HYDROS (PRCT)?
Where can UK healthcare providers learn more about HYDROS and Aquablation (PRCT)?
Will HYDROS be available outside the UK in 2026 and what is the timeline (PRCT)?
